Status:
COMPLETED
Safety of Lumiracoxib in Patients With Osteoarthritis
Lead Sponsor:
Novartis
Conditions:
Osteoarthritis
Eligibility:
All Genders
50-90 years
Phase:
PHASE3
Brief Summary
This safety study evaluated the incidence of gastrointestinal adverse events and edema in patients with osteoarthritis treated with lumiracoxib and rofecoxib as comparator
Eligibility Criteria
Inclusion
- Age \>=50 years old
- Primary osteoarthritis in hip, hand, knee or spine for at least 3 month
- Pain in the target joint of moderate intensity
- Written informed consent
Exclusion
- Secondary osteoarthritis
- Active upper gastro intestinal tract ulceration
- Inflammatory joint disease
- Gout
- Clinically significant hepatic or renal disease
- Other in and exclusion criteria may apply
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2001
Estimated Enrollment :
309 Patients enrolled
Trial Details
Trial ID
NCT00637949
Start Date
December 1 2000
End Date
March 1 2001
Last Update
March 18 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.